Search results
Results from the WOW.Com Content Network
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month.
Zealand Pharma (OTC: ZLDP.F) is a biotech with a pipeline that's full of promising clinical-stage weight-loss programs, among other indications. In particular, its lead anti-obesity program, a ...
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge ... Novo Nordisk has seen its share price leap 137 percent in just two years, from $53 a share in May 2022 to $126 in May 2024 ...
That program will soon enter phase 2b clinical trials, and the early results look promising. Management thinks that this candidate could help patients lose as much as 20% of their body mass in a ...
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished. ... 800-290-4726 more ways to reach us. Sign in. Mail. 24/7 Help. For premium support please call:
Registered dietitians share their top (simple!) tips.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The news has boosted the stocks of both Novo Nordisk , which also makes Ozempic, and Eli Lilly , maker of Mounjaro, a Type-2 diabetes drug also linked to weight loss. Both companies were up more ...